ClinicalTrials.gg
RecruitingNCT07850882Updated Sep 30, 2026

A Prospective Real-World Observational Study of Intratumoral Oncolytic Virus Injection Combined With Immune Checkpoint Inhibitors for Metastatic Tumors (Colorectal Cancer, Gastric Cancer, and Hepatocellular Carcinoma)

An observational study in Colorectal Cancer (CRC), Gastric Cancer (GC) and Hepatocellular Carcinoma (HCC), sponsored by Jie Yuan,MD. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Jie Yuan,MD · Observational

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,134 studies in Colorectal Neoplasms with a site in China — 526 open to participants now, 603 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
229th of 243
30 · median 400
Started
2026
with 112 others
Observational
243 of 1,134
92 open now
Primary completion
2028-02
later than 480 of 602 live
Registered
1,112th of 1,134
by date

Among the 1,134 studies in Colorectal Neoplasms with a site in China, this one is the 229th largest by planned enrollment of the 243 observational ones that give a count, is one of 113 that started in 2026, is one of 243 observational ones, reaches primary completion later than 480 of the 602 other live ones, and was the 1,112th registered.

Colorectal Neoplasms

6,545 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

526 of the 1,134 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

520 more — sign in →

All 526 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,134 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this single-arm, open-label, prospective clinical trial is to evaluate the safety, feasibility, and preliminary antitumor activity of intratumoral oncolytic virus (H101, recombinant human type 5 adenovirus) combined with immune checkpoint inhibitors (ICIs), and to explore the dynamic remodeling of the tumor immune microenvironment and potential predictive biomarkers, in patients with advanced metastatic colorectal cancer, gastric cancer, or hepatocellular carcinoma who have failed multiple prior lines of therapy.

The main questions it aims to answer are:

What are the incidence of treatment-related adverse events and serious adverse events, and the completion rate of the combination therapy (safety and feasibility)? What is the objective response rate and local control rate per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (preliminary antitumor activity)? How does the combination therapy reshape the tumor immune microenvironment in terms of immune cell infiltration, subset proportions, functional status, and signaling pathways, and which differentially expressed genes or immune cell subtypes are associated with clinical response? This is a single-arm study; there is no comparator group.

Participants will:

Receive intratumoral H101 injection once per cycle (dose stratified by lesion size), followed 5-7 days later by intravenous ICI [Anti-Programmed Cell Death Protein 1 Antibody (anti-PD-1) with or without Anti-Cytotoxic T-Lymphocyte-Associated Protein 4 Antibody (anti-CTLA-4)], repeated every 2-3 weeks for a total of 4 cycles.

Provide paired tumor biopsy samples and peripheral blood specimens at baseline and after 4 cycles for single-cell RNA sequencing and biomarker analyses.

Undergo routine clinical assessments, imaging for tumor response evaluation, and safety monitoring with adverse event grading per Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0).

Read the detailed description

Background and Rationale Advanced metastatic colorectal cancer, gastric cancer, and hepatocellular carcinoma remain major causes of cancer-related mortality worldwide, particularly after failure of multiple lines of standard systemic therapies. Immune checkpoint inhibitors (ICIs) have shown limited efficacy as monotherapy in these tumors, partly due to an immunosuppressive tumor microenvironment (TME) characterized by sparse T-cell infiltration, high myeloid-derived suppressor cell (MDSC) accumulation, and dysfunctional antigen presentation. Oncolytic viruses, such as H101 (recombinant human type 5 adenovirus), can selectively replicate in tumor cells, induce immunogenic cell death, and release tumor-associated antigens, thereby converting a "cold" TME into a "hot" one. Preclinical and early clinical data suggest that intratumoral administration of oncolytic viruses may synergize with systemic ICIs by enhancing T-cell priming, increasing Programmed Death-Ligand 1 (PD-L1) expression, and remodeling the immune cell landscape. However, real-world evidence in the digestive cancer setting, especially for heavily pretreated patients, is scarce. This investigator-initiated study is therefore designed to generate preliminary data on the combination's safety, feasibility, and biological activity in a routine clinical practice context.

Study Objectives Primary objective: To assess the safety [Treatment-Related Adverse Events / Serious Adverse Events(TRAEs/SAEs)], feasibility (treatment completion and modification rates), and preliminary antitumor activity (ORR and LCR by RECIST 1.1) of intratumoral H101 plus ICIs.

Secondary objective: To evaluate disease control rate (DCR), progression-free survival (PFS), and longitudinal changes in the TME, including immune cell infiltration (T cells, NK cells, dendritic cells, macrophages), subset proportions, functional markers, and immune-related signaling pathways.

Exploratory objective: To identify potential predictive biomarkers of response by integrating single-cell RNA sequencing (scRNA-seq) data from paired tumor biopsies and peripheral blood, and to characterize the molecular and cellular mechanisms underlying the combination therapy.

Study Design This is a single-center, prospective, open-label, single-arm observational study conducted in a real-world clinical setting. Although the treatment is protocol-specified, all clinical decisions are made per routine multidisciplinary team (MDT) evaluation; the study does not add extra interventions beyond planned therapy but standardizes data collection, efficacy assessment, safety monitoring, and biospecimen banking. A total of 30-45 patients (10-15 per cancer type) will be enrolled.

Participant Selection Eligible patients are adults (≥18 years) with histologically or cytologically confirmed advanced metastatic colorectal cancer, gastric cancer, or hepatocellular carcinoma, who have progressed on or were intolerant to at least two prior lines of systemic therapy (including chemotherapy and/or targeted agents). Patients must have at least one measurable lesion suitable for intratumoral injection per RECIST 1.1, adequate organ function, and an Eastern Cooperative Oncology Group performance status of 0-2. Key exclusion criteria include prior treatment with oncolytic viruses or ICIs (unless washout >6 months for ICIs), active central nervous system metastases, uncontrolled intercurrent illnesses, or known allergy to adenoviral vectors. All patients are assessed by the institutional MDT and deemed appropriate for the combination regimen.

Treatment Protocol

The treatment schedule consists of 4 cycles, each lasting 2-3 weeks, as follows:

Cycle 1: On Day 1, H101 is injected intratumorally at a dose stratified by the largest lesion diameter: ≤5 cm → 5.0×10¹¹ viral particles (vp); >5 cm → 1.0×10¹² vp, divided into multiple injection points if necessary. On Day 5-7 (window), the first dose of ICI is administered intravenously: either anti-PD-1 monotherapy (e.g., sintilimab, toripalimab, or pembrolizumab at standard approved doses) or a combination of anti-PD-1 plus anti-CTLA-4 (e.g., ipilimumab at 1 mg/kg) per the treating physician's discretion and local label.

Subsequent cycles (2-4): H101 injection is repeated on Day 1 of each cycle, followed by ICI on Day 5-7. Dose modifications for toxicity follow standard guidelines; treatment delays of up to 2 weeks are permitted, but discontinuation is required if toxicity does not resolve to ≤ Grade 1 within that period.

Assessments and Data Collection Safety: All adverse events are recorded and graded using CTCAE v5.0 from the first dose until 30 days after the last dose. SAEs are reported within 24 hours.

Efficacy: Tumor imaging (CT/MRI) is performed at baseline and after cycle 4 (or earlier if clinically indicated). Responses are independently reviewed by two radiologists according to RECIST 1.1. PFS is calculated from the first treatment date to disease progression or death from any cause.

Biomarker sampling: Paired tumor biopsies (core needle or fine-needle aspiration from the injected lesion) and peripheral blood (10 mL) are collected at baseline (within 7 days before first H101) and at the end of cycle 4 (within 7 days after the last ICI). Samples are processed for scRNA-seq, flow cytometry, and multiplex cytokine assays.

Data management: All data are entered into a secured electronic case report form (eCRF) with unique subject codes; personal identifiers are removed to protect privacy.

Statistical Methods

Given the exploratory nature, the sample size is not based on formal power calculation but is considered adequate to provide descriptive estimates and generate hypotheses. Continuous variables will be summarized as mean (SD) or median (IQR); categorical variables as frequencies and percentages. For primary endpoints:

Safety and feasibility will be reported with descriptive statistics. ORR and LCR will be calculated with exact 95% confidence intervals (Clopper-Pearson method).

DCR will be similarly reported. PFS will be estimated using the Kaplan-Meier method, with median time and 95% CI.

For paired immune parameters (e.g., cell subset frequencies, cytokine levels), changes from baseline to post-treatment will be assessed using paired t-tests for normally distributed data or Wilcoxon signed-rank tests for non-normal distributions. All statistical tests are two-sided, with a significance level of α=0.05 (exploratory, no multiplicity adjustment).

For scRNA-seq data, after quality control and normalization, unsupervised clustering (Seurat) will be performed to identify cell populations; differential expression analysis between responder and non-responder groups, or between pre- and post-treatment, will employ the MAST or Wilcoxon rank-sum test. Gene set enrichment analysis (GSEA) and pathway analysis (GO/KEGG) will be applied to characterize functional changes. Correlations between baseline immune features and clinical outcomes will be explored using Spearman's rank correlation.

Ethical and Regulatory Considerations The study protocol has been approved by the institutional review board/ethics committee of the participating center. Written informed consent will be obtained from all patients prior to any study-specific procedures. The study will be conducted in full compliance with the Declaration of Helsinki (Fortaleza revision), Good Clinical Practice guidelines, and all applicable local regulations. Any protocol amendments will be submitted for ethical review and updated on this registry.

Expected Significance This study is among the first to prospectively evaluate the H101-ICI combination in a real-world, heavily pretreated population of three major digestive cancers. The integrated clinical and multi-omics data are expected to provide crucial evidence on the safety profile and clinical benefit of this approach, while the mechanistic explorations may uncover immune biomarkers that guide patient selection and combination strategy refinement. The findings will inform the design of larger, randomized controlled trials and ultimately contribute to the development of personalized immunotherapeutic regimens for patients with limited treatment options.

03

Conditions studied

  • Colorectal Cancer (CRC)
  • Gastric Cancer (GC)
  • Hepatocellular Carcinoma (HCC)

Keywords

  • Oncolytic virus
  • H101
  • Immune checkpoint inhibitors
  • Intratumoral injection
  • Metastatic cancer
  • Abscopal response
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study is designed to enroll a total of 30 patients, aged 18 to 75 years, with advanced, multiply metastatic colorectal cancer, gastric cancer, and hepatocellular carcinoma who have failed multiple lines of prior systemic therapy (approximately 10-15 cases per cancer type). Subjects will be primarily recruited from the patient population at Foshan Fosun Chancheng Hospital. To be eligible, subjects must meet all inclusion criteria and none of the exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18-75 years.
  • confirmed solid tumors, including superficial lesions and intra-abdominal or intrathoracic tumors, that are amenable to intratumoral injection with a longest diameter ≥1.0 cm.
  • For superficial metastatic lesions that have not received local radiotherapy, ablation, or surgical resection; if such treatments have been performed, at least 4 weeks must have elapsed since completion and the lesion must show documented progression.
  • Prior systemic therapy must have been completed at least 4 weeks or 5 half-lives ago, and the patient must have recovered from previous treatment-related toxicities.
  • Adequate cardiopulmonary, hepatic, and renal function to tolerate Oncorine® (H101) intratumoral injection.
  • The patient and their family members are willing to participate in this study and provide written .

Exclusion criteria

Exclusion Criteria:

  • Peripheral blood lymphocyte count \<1.0×10⁹/L;
  • Target superficial or body cavity tumors located adjacent to major blood vessels or nerves, with a high risk of puncture or injection; or lesions with active infection or ulceration;
  • Known severe to Oncorine® (H101) or any of its components;
  • Active intra-abdominal infection or uncontrolled ascites;
  • Currently receiving systemic or other potent agents;
  • Planned receipt of other antitumor therapies during the study period (except supportive care);
  • Concurrent other or a history of prior malignancy;
  • Tumors complicated by rupture with hemorrhage, massive gastrointestinal bleeding, intestinal obstruction, or other conditions requiring emergency surgery;
  • (ASA) classification ≥ IV and/or (ECOG) performance status score >2;
  • Active disease, or history of autoimmune disease requiring systemic therapy; uncontrolled severe infections (e.g., , active with HBV-DNA above the lower limit of detection, active ); severe cardiovascular or cerebrovascular disease; history of organ transplantation; active bleeding or high bleeding risk;
  • History of severe psychiatric illness;
  • Pregnant or breastfeeding women;
  • Uncontrolled active infection;
  • Other clinical or laboratory conditions that, in the opinion of the nvestigator, render the patient unsuitable for participation in this trial.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Treatment group

    H101 (Recombinant Human Adenovirus Type 5 Injection)+Anti-Programmed Cell Death Protein 1 Antibody(Anti-PD-1 antibody) ± Anti-Cytotoxic T-Lymphocyte-Associated Protein 4 Antibody(anti-CTLA-4 antibody) H101 (Recombinant Human Adenovirus Type 5 Injection) Route of administration: Intratumoral injection Dose: Stratified dosing according to lesion size, using the dose specified in the package insert and the dose based on prior clinical experience (multipoint injection) Frequency: Once per cycle Treatment course: 2-3 weeks per cycle, for a total of 4 cycles Anti-PD-1 antibody ± anti-CTLA-4 antibody Initiation time: 7 ± 2 days after the first H101 injection Administration schedule: Once per cycle.

06

What researchers measure

Primary outcomes

  1. Preliminary antitumor activity

    Radiographic tumor response assessment using RECIST 1.1 criteria

    Time frame: Baseline and 6-8 weeks after the end of treatment

  2. Treatment feasibility

    The completion rate of the combination regimen (H101 intratumoral injection plus ICIs), and the proportion of dose adjustments, treatment delays, interruptions, or discontinuations resulting from toxicity or other reasons.

    Time frame: During the treatment period (up to 4 cycles, each cycle 2-3 weeks)

  3. Incidence of Adverse Events

    National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

    Time frame: From first dose of study treatment through 30 days after the last dose (up to approximately 8-12 weeks)

Secondary outcomes

  1. Disease Control Rate

    Radiographic tumor response assessment using RECIST 1.1 criteria

    Time frame: Baseline and up to approximately 6 months (including 6-8 weeks after the end of treatment)

  2. Changes in Peripheral Blood Immunological Parameters

    Peripheral blood laboratory assays

    Time frame: Baseline and after completion of 4 treatment cycles (each cycle 2-3 weeks; approximately 8-12 weeks)

  3. Tumor Immune Microenvironment (TME) Changes

    peripheral blood tests and single-cell sequencing of tumor tissues, among others

    Time frame: Baseline and after completion of 4 treatment cycles (each cycle 2-3 weeks; approximately 8-12 weeks)

  4. Progression-Free Survival

    Based on comprehensive clinical and imaging assessment

    Time frame: From first dose of study treatment until disease progression per RECIST v1.1 or death from any cause, whichever occurs first (up to approximately 2 years)

  5. Correlation analysis will be performed between TME changes (e.g., immune cell infiltration, cytokine profiles) and clinical efficacy endpoints including ORR, DCR, and PFS.

    Based on comprehensive clinical and imaging assessment

    Time frame: Baseline (pre-treatment) through the final clinical efficacy assessment, including disease progression or death, up to approximately 2 years

  6. Single-cell RNA sequencing (scRNA-seq) will be performed on tumor tissues pre- and post-treatment to assess alterations in cellular composition, intercellular communication, immune-related pathways, a

    Single-cell RNA sequencing (scRNA-seq)

    Time frame: Baseline and after completion of 4 treatment cycles (each cycle 2-3 weeks; approximately 8-12 weeks)

07

Study locations

1 of 1 sites recruiting
  • Foshan Fosun Chancheng Hospital
    Guangdong, Foshan, China
    Recruiting
    • Jie Yuan, Doctoral degree · Contactcandlewjy@163.com · +86 13016007353
    • Jie Yuan, Doctoral degree · Contact0757-82778323
08

References and documents

Publications

  • Huang Z, Guo H, Lin L, Li S, Yang Y, Han Y, Huang W, Yang J. Application of oncolytic virus in tumor therapy. J Med Virol. 2023 Apr;95(4):e28729. doi: 10.1002/jmv.28729. PubMed 37185868 ↗
  • Lovatt C, Parker AL. Oncolytic Viruses and Immune Checkpoint Inhibitors: The "Hot" New Power Couple. Cancers (Basel). 2023 Aug 19;15(16):4178. doi: 10.3390/cancers15164178. PubMed 37627206 ↗
  • Reddy R, Yan SC, Hasanpour Segherlou Z, Hosseini-Siyanaki MR, Poe J, Perez-Vega C, Chiocca EA, Lucke-Wold B. Oncolytic viral therapy: a review and promising future directions. J Neurosurg. 2023 Aug 25;140(2):319-327. doi: 10.3171/2023.6.JNS23243. Print 2024 Feb 1. PubMed 37877961 ↗
  • Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023 Apr 11;8(1):156. doi: 10.1038/s41392-023-01407-6. PubMed 37041165 ↗
  • Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023 Mar;20(3):160-177. doi: 10.1038/s41571-022-00719-w. Epub 2023 Jan 11. PubMed 36631681 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect participant privacy and confidentiality.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Feb 2028, 17 months later.

Of 529 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 17 months is below that.

Counting every sponsor, half of 646 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2026
First posted
Sep 30, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Feb 29, 2028
CompletionEst.
Feb 29, 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850882
Lead sponsor
Jie Yuan,MD
Responsible party
Jie Yuan,MD (Associate Chief Physician, Foshan Fosun Chancheng Hospital) — Sponsor-investigator
First posted
Sep 30, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Feb 29, 2028 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Jie Yuan, Doctoral degree
Contact
candlewjy@163.com
+86 13016007353

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion